This one comes to us courtesy of an anonymous commenter, who saw it — and posted it — whilst I was attending to other matters. Clearly Ex-CEO Hassan’s rhetoric was egregiously overblown (on boceprevir), given that he too knew of the Phase IIb (and later, Phase III) top-line trial results, between these two Hep C candidates.
In any event, here’s Matt Herper (writing for Forbes) on it — do go read it all:
. . . .Vertex Pharmaceuticals has been going up against drug giant Merck in a marketing battle to treat hepatitis C — and so far it’s winning in a big way.
Despite a partnership with Roche, one of the traditional leaders in the hepatitis C market, Vertex’s Incivek is being prescribed four times as often as Merck’s Victrelis, analysts say. This morning, Geoffrey Porges of Sanford C. Bernstein, a Vertex bull, wrote in a note to investors that Incivek is doing even better than they think.
Porges says that if prescriptions of Incivek were to stop growing entirely, the drug would still generate 2011 sales of $725 million, still slightly above the $700 million average of forecasts by Wall Street analysts. If growth rapidly slows, Incivek will still generate $900 million. If sales keep growing at their current rate, he says that Incivek sales could hit $1.2 billion — impressive given that the medicine was only approved this year. . . .
Indeed — it was only approved in May of this yead. And so, this was yet another pig in a poke, sold to Merck by Ex-CEO Hassan — just as we’ve consistently said, since early 2009. Finally, the proof is out.